Phase 2 Leukaemia Trial, Recruiting NCT04010877 Sponsor: Shenzhen Geno-Immune Medical Institute Condition: Leukaemia
Back to Leukaemia

Phase 2 Leukaemia Trial, Recruiting

NCT04010877
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be older than 6 months of age.
  • Your leukemia (AML) cells must have been tested and confirmed to carry certain markers called CLL-1, CD123, and/or CD33, found through a lab test or bone marrow/blood analysis.
  • You must be in reasonably good general health, able to carry out normal activity with only minor difficulty, and expected to live longer than 3 months (confirm with trial site).
  • Your heart, liver, and kidneys must be functioning well enough to meet specific lab test thresholds set by the trial team.
  • Your hemoglobin (a measure of red blood cells) must be at or above a minimum level set by the trial (confirm with trial site for exact value).
  • You must not have any medical reason that would prevent a cell collection procedure.
  • You must be able to understand the trial and be willing to sign a written consent form agreeing to take part.

Who may not be able to join:

  • People with a serious illness or uncontrolled infection that would make it unsafe to follow the trial plan.
  • People with an active bacterial, fungal, or viral infection that is not being successfully treated.
  • People who are known to have HIV, hepatitis B, or hepatitis C.
  • Women who are pregnant or currently breastfeeding.
  • People who have taken steroid medicines (such as corticosteroids) as a full-body treatment within the week before joining the trial.
  • People who have previously received any gene therapy treatment.
  • People who, in the trial doctors' judgement, may be unable to follow the trial requirements for any reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 2 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Shenzhen Geno-Immune Medical Institute
Registry
ClinicalTrials.gov
Start date
1 August 2025
Est. completion
31 July 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Safety of infusion

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov